Nosa Med AB (NOSA) - Net Assets
Based on the latest financial reports, Nosa Med AB (NOSA) has net assets worth Skr41.06 Million SEK (≈ $4.42 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr64.71 Million ≈ $6.96 Million USD) and total liabilities (Skr23.65 Million ≈ $2.55 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NOSA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr41.06 Million |
| % of Total Assets | 63.45% |
| Annual Growth Rate | -14.49% |
| 5-Year Change | 5.01% |
| 10-Year Change | N/A |
| Growth Volatility | 61.86 |
Nosa Med AB - Net Assets Trend (2016–2025)
This chart illustrates how Nosa Med AB's net assets have evolved over time, based on quarterly financial data. See Nosa Med AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Nosa Med AB (2016–2025)
The table below shows the annual net assets of Nosa Med AB from 2016 to 2025. For live valuation and market cap data, see how much is Nosa Med AB worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr41.06 Million ≈ $4.42 Million |
+148.02% |
| 2024-12-31 | Skr16.56 Million ≈ $1.78 Million |
-38.11% |
| 2023-12-31 | Skr26.75 Million ≈ $2.88 Million |
+45.90% |
| 2022-12-31 | Skr18.34 Million ≈ $1.97 Million |
-53.11% |
| 2021-12-31 | Skr39.10 Million ≈ $4.21 Million |
-61.53% |
| 2020-12-31 | Skr101.64 Million ≈ $10.94 Million |
-45.89% |
| 2019-12-31 | Skr187.85 Million ≈ $20.22 Million |
-6.26% |
| 2018-12-31 | Skr200.39 Million ≈ $21.56 Million |
+4.25% |
| 2017-12-31 | Skr192.22 Million ≈ $20.69 Million |
+14.38% |
| 2016-12-31 | Skr168.06 Million ≈ $18.09 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Nosa Med AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8817600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr13.01 Million | 31.68% |
| Other Comprehensive Income | Skr-126.00K | -0.31% |
| Other Components | Skr139.72 Million | 340.27% |
| Total Equity | Skr41.06 Million | 100.00% |
Nosa Med AB Competitors by Market Cap
The table below lists competitors of Nosa Med AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Daedong Metals Co. Ltd
KQ:020400
|
$14.67 Million |
|
T3 Defense Inc.
NYSE:DFNS
|
$14.68 Million |
|
Audalia Resources Ltd
AU:ACP
|
$14.69 Million |
|
Jocil Limited
NSE:JOCIL
|
$14.70 Million |
|
Rajshree Polypack Limited
NSE:RPPL
|
$14.67 Million |
|
WhiteSmoke Software Ltd
TA:WSMK
|
$14.66 Million |
|
Air Industries Group
NYSE MKT:AIRI
|
$14.65 Million |
|
Cheetah Holdings Bhd
KLSE:7209
|
$14.65 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nosa Med AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,556,000 to 41,063,000, a change of 24,507,000 (148.0%).
- Net loss of 8,041,000 reduced equity.
- New share issuances of 32,255,000 increased equity.
- Other comprehensive income decreased equity by 126,000.
- Other factors increased equity by 419,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-8.04 Million | -19.58% |
| Share Issuances | Skr32.26 Million | +78.55% |
| Other Comprehensive Income | Skr-126.00K | -0.31% |
| Other Changes | Skr419.00K | +1.02% |
| Total Change | Skr- | 148.02% |
Book Value vs Market Value Analysis
This analysis compares Nosa Med AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.05x to 3.02x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr11.22 | Skr0.52 | x |
| 2017-12-31 | Skr11.03 | Skr0.52 | x |
| 2018-12-31 | Skr9.98 | Skr0.52 | x |
| 2019-12-31 | Skr7.59 | Skr0.52 | x |
| 2020-12-31 | Skr3.20 | Skr0.52 | x |
| 2021-12-31 | Skr0.81 | Skr0.52 | x |
| 2022-12-31 | Skr0.11 | Skr0.52 | x |
| 2023-12-31 | Skr0.17 | Skr0.52 | x |
| 2024-12-31 | Skr0.08 | Skr0.52 | x |
| 2025-12-31 | Skr0.17 | Skr0.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nosa Med AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -19.58%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -33.63%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 1.58x
- Recent ROE (-19.58%) is above the historical average (-98.02%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -10.89% | 0.00% | 0.00x | 1.02x | Skr-35.11 Million |
| 2017 | -12.95% | -10037.90% | 0.00x | 1.04x | Skr-44.12 Million |
| 2018 | -20.97% | -799.52% | 0.02x | 1.07x | Skr-62.05 Million |
| 2019 | -39.27% | -3810.07% | 0.01x | 1.08x | Skr-92.55 Million |
| 2020 | -225.42% | -16760.42% | 0.01x | 1.14x | Skr-239.28 Million |
| 2021 | -149.76% | -1000.43% | 0.15x | 1.03x | Skr-62.48 Million |
| 2022 | -266.00% | -260.18% | 0.32x | 3.23x | Skr-18.49 Million |
| 2023 | -174.03% | -447.94% | 0.31x | 1.24x | Skr-49.23 Million |
| 2024 | -61.36% | -63.10% | 0.78x | 1.25x | Skr-11.81 Million |
| 2025 | -19.58% | -33.63% | 0.37x | 1.58x | Skr-12.15 Million |
Industry Comparison
This section compares Nosa Med AB's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $154,871,216
- Average return on equity (ROE) among peers: -59.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nosa Med AB (NOSA) | Skr41.06 Million | -10.89% | 0.58x | $14.67 Million |
| Acarix A/S (ACARIX) | $100.54 Million | -51.52% | 0.18x | $31.21 Million |
| Arcoma AB (ARCOMA) | $49.53 Million | 2.76% | 0.92x | $13.61 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $387.11 Million | -0.84% | 0.62x | $54.96 Million |
| BICO Group AB (BICO) | $549.64 Million | 0.11% | 0.10x | $124.14 Million |
| Boule Diagnostics AB (BOUL) | $192.86 Million | 6.07% | 0.41x | $13.37 Million |
| CellaVision AB (CEVI) | $206.18 Million | 29.00% | 0.24x | $351.14 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $3.68 Million | -18.24% | 0.50x | $11.99 Million |
| Chordate Medical Holding AB (CMH) | $15.09 Million | -193.46% | 0.46x | $29.05K |
| C-Rad AB (publ) (CRAD-B) | $38.03 Million | -55.21% | 0.62x | $127.56 Million |
| Duearity AB (DEAR) | $6.06 Million | -318.56% | 0.99x | $331.97K |
About Nosa Med AB
Nosa Plugs AB, a medical technology company, develops, manufactures, and sells intranasal breathing products in Sweden, rest of Europe, the United States, Canada, and internationally. The company offers NOSA allergy filter that filters airborne allergens, such as pollen, pet dander, dust, and mold; NOSA smell training, a smell training medical device to improve the sense of smell for individuals … Read more